{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:54:05Z","timestamp":1787064845015,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jiac.2018.01.010","type":"journal-article","created":{"date-parts":[[2018,3,10]],"date-time":"2018-03-10T19:59:52Z","timestamp":1520711992000},"page":"434-442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan \u2013 Results of a randomised, multicentre phase 3 study"],"prefix":"10.1016","volume":"24","author":[{"given":"Hiroshige","family":"Mikamo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Takesue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Tanigawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Tanimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2018.01.010_bib1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1086\/533452","article-title":"Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE","volume":"197","author":"Rice","year":"2008","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jiac.2018.01.010_bib2","series-title":"Antimicrobial resistance. Global report on surveillance","author":"WHO","year":"2014"},{"key":"10.1016\/j.jiac.2018.01.010_bib3","unstructured":"Japan nosocomial infection surveillance (JANIS) antimicrobial-resistant bacterial infection division. Annual open report 2015. Date of publication (Japanese Version): September 21, 2016."},{"key":"10.1016\/j.jiac.2018.01.010_bib4","unstructured":"Japan nosocomial infections surveillance (JANIS) clinical laboratory division. Annual open report 2015. Date of publication (English Version): April 4, 2017."},{"key":"10.1016\/j.jiac.2018.01.010_bib5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jiac.2017.03.010","article-title":"Antimicrobial susceptibility of pathogens isolated from surgical site infections in Japan: comparison of data from nationwide surveillance studies conducted in 2010 and 2014\u20132015","volume":"23","author":"Takesue","year":"2017","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2018.01.010_bib6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/jac\/39.4.471","article-title":"Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus","volume":"39","author":"Watanabe","year":"1997","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2018.01.010_bib7","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jac\/dkm369","article-title":"Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan","volume":"60","author":"Kohno","year":"2007","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2018.01.010_bib8","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s10156-010-0076-2","article-title":"Methicillin resistant Staphylococcus aureus in a Japanese community hospital: 5-year experience","volume":"16","author":"Kunishima","year":"2010","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2018.01.010_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/TCRM.S23875","article-title":"Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus","volume":"8","author":"Hagihara","year":"2012","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jiac.2018.01.010_bib10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10156-012-0501-9","article-title":"Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections","volume":"19","author":"Aikawa","year":"2013","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2018.01.010_bib11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.5414\/CP201739","article-title":"Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection","volume":"51","author":"Ogawa","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jiac.2018.01.010_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40545-016-0087-1","article-title":"Impact of switching from intravenous to oral linezolid therapy in Japanese patients: a retrospective cohort study","volume":"9","author":"Tanaka","year":"2016","journal-title":"J\u00a0Pharm Policy Pract"},{"key":"10.1016\/j.jiac.2018.01.010_bib13","first-page":"323","article-title":"Practical guidelines for the management and treatment of infections caused by MRSA 2017","volume":"65","author":"Niki","year":"2017","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2018.01.010_bib14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40121-014-0035-9","article-title":"Tolerability of high doses of daptomycin in the treatment of prosthetic vascular graft infection: a retrospective study","volume":"3","author":"Legout","year":"2014","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiac.2018.01.010_bib15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.amjmed.2009.05.031","article-title":"Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?","volume":"123","author":"Hazlewood","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.jiac.2018.01.010_bib16","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10156-010-0182-1","article-title":"Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy","volume":"17","author":"Takahashi","year":"2011","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2018.01.010_bib17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s10156-010-0080-6","article-title":"Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction","volume":"17","author":"Tsuji","year":"2011","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2018.01.010_bib18","first-page":"172","article-title":"Drug-related mitochondrial optic neuropathies","volume":"33","author":"Wang","year":"2013","journal-title":"J\u00a0Neuro Ophthalmol"},{"key":"10.1016\/j.jiac.2018.01.010_bib19","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s11096-014-9961-6","article-title":"Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients","volume":"36","author":"Hirano","year":"2014","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.jiac.2018.01.010_bib20","first-page":"139","article-title":"Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens","volume":"6","author":"Matsumoto","year":"2014","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.jiac.2018.01.010_bib21","first-page":"279","article-title":"The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis","volume":"40","author":"Ichie","year":"2015","journal-title":"J\u00a0Clin Pharm Therapeut"},{"key":"10.1016\/j.jiac.2018.01.010_bib22","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jiac.2016.05.003","article-title":"A\u00a0retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia","volume":"22","author":"Hanai","year":"2016","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2018.01.010_bib23","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.ejmech.2011.01.014","article-title":"Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent","volume":"46","author":"Im","year":"2011","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jiac.2018.01.010_bib24","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1128\/AAC.00663-10","article-title":"Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations","volume":"54","author":"Locke","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2018.01.010_bib25","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.jiac.2018.01.010_bib26","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2018.01.010_bib27","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/AAC.03688-14","article-title":"Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections","volume":"59","author":"Shorr","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2018.01.010_bib28","doi-asserted-by":"crossref","first-page":"7198","DOI":"10.1128\/AAC.03509-14","article-title":"Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials","volume":"58","author":"Lodise","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2018.01.010_bib29","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/phar.1337","article-title":"Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug","volume":"34","author":"Flanagan","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2018.01.010_bib30","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/phar.1458","article-title":"Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid","volume":"34","author":"Flanagan","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2018.01.010_bib31","unstructured":"Tanaka T, Hayashi Y, Okumura K, Yoshikawa K, Kato M, Kanatani KT, et\u00a0al. Oral bioavailability of tedizolid in healthy Japanese subjects in a Phase I study. Presented at the European congress of clinical microbiology and infectious diseases meeting, Barcelona, Spain, 10\u201313 May, 2014; poster 1718."},{"key":"10.1016\/j.jiac.2018.01.010_bib32","unstructured":"Tanaka T, Hayashi Y, Okumura K, Yoshikawa K, Kato M, Kanatani KT, et\u00a0al. Pharmacokinetics of 7-day multiple-dose tedizolid phosphate in healthy Japanese subjects in a Phase I placebo-controlled study. Presented at the European congress of clinical microbiology and infectious diseases meeting, Barcelona, Spain, 10\u201313 May, 2014; poster 1723."},{"key":"10.1016\/j.jiac.2018.01.010_bib33","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.clinthera.2016.06.014","article-title":"Pharmacokinetics and safety of tedizolid after single and multiple intravenous\/oral sequential administrations in healthy Chinese subjects","volume":"38","author":"Chen","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.jiac.2018.01.010_bib34","unstructured":"Safety and Efficacy of BAY1192631 in Japanese Patients with Methicillin-resistant Staphylococcus aureus (MRSA) Infections. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01967225."},{"key":"10.1016\/j.jiac.2018.01.010_bib35","unstructured":"Zyvox\u00ae (linezolid). Common Technical Document 2006 (Japanese). Available at: http:\/\/www.pmda.go.jp\/drugs\/2006\/P200600016\/40007900_21300AMY00122_K101_2.pdf."},{"key":"10.1016\/j.jiac.2018.01.010_bib36","unstructured":"Cubicin\u00ae (daptomycin). Common Technical Document 2011 (Japanese). Available at: http:\/\/www.pmda.go.jp\/drugs\/2011\/P201100126\/170050000_22300AMX00604000_K100_1.pdf."},{"key":"10.1016\/j.jiac.2018.01.010_bib37","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.jiac.2018.01.010_bib38","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"10.1016\/j.jiac.2018.01.010_bib39","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1128\/AAC.00948-12","article-title":"A\u00a0randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections","volume":"56","author":"Noel","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2018.01.010_bib40","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s12325-013-0038-z","article-title":"Moxifloxacin in complicated skin and skin structure infections (cSSSIs): a prospective, international, non-interventional, observational study","volume":"30","author":"Bogner","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.jiac.2018.01.010_bib41","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijantimicag.2014.04.007","article-title":"Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria","volume":"44","author":"Eckmann","year":"2014","journal-title":"J\u00a0Antimicrob Agents"},{"key":"10.1016\/j.jiac.2018.01.010_bib42","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.amjsurg.2009.08.045","article-title":"Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus","volume":"199","author":"Itani","year":"2010","journal-title":"Am J Surg"},{"issue":"Suppl 2","key":"10.1016\/j.jiac.2018.01.010_bib43","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.cmi.2015.03.023","article-title":"Implementing criteria-based early switch\/early discharge programmes: a European perspective","volume":"21","author":"Nathwani","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2018.01.010_bib44","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/pds.1547","article-title":"Adverse events associated with prolonged antibiotic use","volume":"17","author":"Meropol","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jiac.2018.01.010_bib45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1370\/afm.1449","article-title":"Risks and benefits associated with antibiotic use for acute respiratory infections: a cohort study","volume":"11","author":"Meropol","year":"2013","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.jiac.2018.01.010_bib46","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bjid.2015.12.007","article-title":"Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections","volume":"20","author":"Ortiz-Covarrubias","year":"2016","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.jiac.2018.01.010_bib47","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/cid\/ciw750","article-title":"Early clinical response as a predictor of late treatment success in patients with acute bacterial skin and skin structure infections: retrospective analysis of 2 randomized controlled trials","volume":"64","author":"Nathwani","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2018.01.010_bib48","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/sj.ijo.0802486","article-title":"Overweight Japanese with body mass indexes of 23.0\u201324.9 have higher risks for obesity-associated disorders: a comparison of Japanese and Mongolians","volume":"28","author":"Shiwaku","year":"2004","journal-title":"Int J Obes Relat Metab Disord"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X18300278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X18300278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:57:19Z","timestamp":1761159439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X18300278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1341321X18300278"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2018.01.010","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan \u2013 Results of a randomised, multicentre phase 3 study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2018.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}